



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

## INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Available online at: <http://www.iajps.com>

Research Article

### A STUDY ON THE ASSESSMENT OF DIAGNOSTIC ACCURACY OF DIFFERENT BIOMARKERS FOR PROSTATE CANCER

<sup>1</sup>Dr Kifayat Tariq, <sup>1</sup>Dr Mehboob Ul Wahab, <sup>2</sup>Dr Mohammad Ishtiaq, <sup>2</sup>Dr Kamran Ahmed

<sup>1</sup>Institute of kidney Diseases Hayatabad Medical Complex Peshawar, <sup>2</sup>Nowshera Medical College

Article Received: December 2018

Accepted: February 2019

Published: March 2019

**Abstract:**

**Objective:** In this research study the use of prostate specific antigen (PSA) and its sub type (fPSA %) free fraction of total prostate specific antigen percent, (PSAD) prostate specific antigen density as a bio marker for prostate cancer (PCa) is discussed. This research study was conducted to find diagnostic tool in prostate cancer such that serum totals PSA, fPSA% & PSAD. In terms of their sensitivity, specificity and overall accuracy.

**Methodology:** 50 patients of prostate cancer were admitted in Institute of kidney Diseases Hayatabad Medical Complex Peshawar from January 2017 to January 2019. To find out the ratio of PSA and fPSA% in serum we used ELISA (Enzyme linked immunosorbent assay) this kit is present anywhere in medical lab. Data related to volume of prostate which is determined by abdominal sonography were used to count prostate specific antigen density & histology of the surgically cut out prostatic organ was conducted for laboratory verification of PCa for a rest of patients. Diagnostic awareness, particularity & accuracy of serum total PSA, fPSA% and PSAD were counted by using basic formulae against microscopic examination of tissue.

**Results:** Microscopic study of tissue showed that in 50 patients forty-one suffer from prostate cancer the mean age of patients were seventy-one.  $2 \pm 10.1$  years old. In these forty-one patient nine cases are those who suffer from Nodular Hyperplasia of Prostate (NHP) with prostate-specific tumor markers of these patients were commonly in the normal ranges. The awareness, particularity and overall diagnoses accuracy for PCa of serum total PSA (at cut off value of greater than ten ng/ml) were eighty.480 percent, eighty eight.900 percent and eighty two percent for serum free PSA (at cut off value of less than twenty five percent), were ninety two.680 percent, seventy seven.800 percent & ninety percent & for PSA density (at a cut off value of greater than point fifteen ng/ ml/cm<sup>3</sup>), were initiate to be ninety percent eighty eight.900 percent & ninety percent individually. Microscopically, twenty-seven (sixty-five point forty-six), thirteen (thirty-one point seventy percent) & one (two.44percent) cases were divided as poorly separated, normally separated & strongly separated carcinoma individually & amazing superiority had very good interaction with all prostate-specific tumor markers.

**Conclusion:** These outcomes stress that diverse prostate-specific tumor markers have great diagnostic prediction with fPSA% & PSA Density have normally best diagnostic accuracy as compare to serum tPSA for PCa.

**Key Words:** Microscopically, Prostate-Specific, Interaction, Carcinoma, Diagnostic, Antigen, Biomarker.

**Corresponding author:****Dr. Kifayat Tariq,**

Institute of kidney Diseases Hayatabad Medical Complex Peshawar.

QR code



Please cite this article in press Kifayat Tariq et al., A Study On The Assessment Of Diagnostic Accuracy Of  
Different Biomarkers For Prostate Cancer., Indo Am. J. P. Sci, 2019; 06(03).

## INTRODUCTION:

PCa is the type of skin cancer mostly common in men and its occurrence is different for every geographic area. From more than fifty years, serum acid phosphatase was considered most common standard to determine the symptom of PCa. Recently, in nineteen sixty-seven, Wang and his teammates determined (PSA) from prostate tissue and since PSA is considered the standard for the diagnosis and additionally its role in the estimate of microscopic response of PCa. In his study standard and biomarker for PCa was considered PSA. If the level of PSA below in general 4 ng/ml has no symptom of PCa on the other if the value of PSA is higher than four ng/ml is considered PCa patient. PSA value between four to ten ng/ml indicates the dangerous zone & more than ten ng/ml strongly consider PCa. But as a diagnostic problem, PSA count greater than four ng/ml has also been found among PCa patients & higher range i.e. greater than four ng/ml is further correlated with many favorable prostatic circumstances exclusively with nodular hyperplasia of prostate (NHP), it is a frequently present in male age fifty years. That is way, endeavor have been formed to better its diagnostic particularity counting age modification, gland volume modification & sequential assessment.

Many examinations have proposed that evaluation of free fraction of PSA (fPSA/tPSA multiply hundred) is an advancement of initial PSA range & treated as good non-invasive analyze tool for PCa. The frequently suggested aspect of free PSA (fPSA) is an combine to PSA in the so called analyze infection zone of PSA. fPSA% is decrease in PCa than other gentle prostatic circumstances & free PSA of twenty five percent show less cause of cancer if it range above twenty five percent the chance of cancer. Moreover, the calculation of ratio of the serum to the size of prostate was tPSA ÷ prostate quantity has also been correspond as an necessary to tPSA for the PCa. PSA density at a cut off value of point fifteen ng/ml/cm<sup>3</sup> higher PSA density show more chance of PCa.

The most common outcome of our research study to find out the best treatment approach for prostate cancer, the current research was attempted to calculate & compare the diagnostic awareness, particularity and efficiency of serum tPSA, fPSA% & PSA density amid imagined PCa cases.

## MATERIAL AND METHOD:

50 patients of prostate cancer were admitted in Institute of kidney Diseases Hayatabad Medical Complex Peshawar from Jan 2017 to Jan 2019. For the examine we used blood specimen 3 mL of blood was collected and follow the test technique to find the level of PSA the serum from a blood were collected after the rotation of blood up to 400rpm for ten min. Enzyme-linked immunosorbent assay were used to

study tPSA test The ELISA for evaluation of PSA was conducted by Ex 808 Multiskan ELISA reader were used for all fifty PCa cases. Two tests are conducted on ELISA one is rabbit anti -PSA antibody directed against and the second was intact PSA for solid state.

The free PSA enzyme-linked immunosorbent assay test was conducted in solid state two-site (sandwiched) immunoassay. An anti-free PSA monoclonal antibody was covered on the front of the micro plate wells and a rabbit anti- PSA antibody classify with horseradish for a tracer peroxidase was used. Prostate quantity (length multiple width multiple anterior posterior diameter multiple point fifty-two) the measured were taken by the help of abdominal ultrasound and PSA density as calculated as follows;  $PSAD = \frac{\text{Serum tPSA}}{\text{Prostate quantity}}$ . Removed prostatic tissue of all patients was secure in ten percent natural buffered formalin. The prostate tissue was processed for test and paraffin enclose, four to five micro meter thicken sequential section was made. One piece was formed from every section and stained with Hematoxylin and Eosin (H&E). [No of specimen along true-plus results ÷ (No of specimen along true -plus results + No of specimen along false-mines results)] x hundred; Specificity = [No of specimen along true-mines results ÷ (No of specimen along true-mines results + No of specimen along false-plus results)] x hundred. Diagnostic accuracy = [No of specimen along true-plus results + No of specimen along true-mines results / No of specimen along true-plus results + No of specimen along false-plus results + No of specimen along false-mines results + No of specimen along true-mines results x hundred.

## RESULTS:


Table-I shows that age and prostate cancer are proportional the mean age of both sex of the patients was seventy-one.2 ± ten.1 years, with age ranging of fifty to ninety-five years. More than forty percent patients were under the age of seventy-one to eighty years with hundred percent PCa. Hospital study cases in fifty cases fifteen were serum tPSA range from four to ten ng/ml, of which were detected as carcinoma and seven as (NHP). Microscopic study report forty-one out of fifty cases suffer from PCa and the rest of nine were NHP. in Table-II. shown interaction of serum tPSA, fPSA and PSA Density with frequency of PCa is Out of 50 clinically attend cases of PCa, thirty-eight (sixty-nine percent) had tPSA was greater than ten ng/ml, forty (eighty percent) had fPSA greater than twenty-five percent & thirty-eight (seventy-six percent) had PSA density of greater than point fifteen with regularity of cancer in ninety-seven percent, ninety-five percent & ninety-seven.36 percent individually.

The rest of nine cases of NHP, seven had their fPSA% less than twenty-five percent eight had PSA density greater than point fifteen ng/ml/cm<sup>3</sup> but seven cases were in the diagnostic dangerous zone for tPSA. According to Gleason's score were divided as poorly separated, normally separated & strongly separated

carcinoma cases were twenty-seven (sixty-five point forty-six), thirteen (thirty-one point seventy percent) & one (two.44 percent) amazing superiority had very good interaction with all prostate-specific tumor markers.

**Table-I: Frequency distribution of prostate cancer among different age groups of Patients (n = 50)**

Age in Years	Total Numbers of Patients	Frequency of PCA
Sixty year or less	Three (sex percent)	Three (hundred percent)
Sixty one to seventy	Fifteen (thirty percent)	Seven (forty six percent)
More than seventy	Twenty one(forty two percent)	Twenty one(hundred percent)



On x-axis the age of patient & on y-axis is frequency of PCa

**Table-II: Detection rate of prostate cancer by different tumor markers total No of cases fifty**

Bio markers	Total cases	No of cancer
serum tPSA Cut-off value is greater than 10	Thirty four (sixty eight %)	Thirty three(ninety seven%)
fPSA cut-off value less than twenty five %	Forty (eighty %)	Thirty eight (ninety five %)
PSA density cut-off value greater than point fifteen	Thirty eight (seventy six %)	Thirty seven(ninety seven.3




Figure II: Detection rate of prostate cancer by different tumor markers (n = 50).

**Table-III: Sensitivity, specificity & Efficiency of all bio markers.**

Bio markers	Sensitivity	specificity	Efficiency
Serum tPSA	Eighty.480 percent	Eighty eight.900 percent	Eighty two percent
fPSA%	Ninety.680 percent	Seventy seven.8 percent	Ninety percent
PSA density	Ninety percent	Eighty eight.900 percent	Ninety percent




Figure-III: Sensitivity, specificity &amp; Efficiency of all bio markers.

**DISCUSSION:**

Recently DRE were conducted for the screening of prostate cancer mostly for men who above from 50 year of age the investigation of patient conducted yearly. For more accurate result fPSA & tPSA was combine with DRE to detect the recent attack of PCa. In Table-I showed that the age of patient proportional to the PCa the chance of prostate cancer was more for aged person. The aims of our research study to assess diagnostic awareness, particularity and efficiency of different prostate specific tumor markers, has assess

all to be useful for the desire, however, fPSA was consider superior tumor marker as compare to tPSA in terms of awareness & efficiency (ninety-two.680 percent vs eighty.480 percent & ninety vs eighty-two percent). These counts are in conformity with others. In ninety-five percent patients of prostate cancer we noted fPSA greater than twenty-five percent except thirty percent patient who had fPSA less than twenty-five percent the mean cut-off value for fPSA for all researchers between tin to twenty-five percent.

In the collection of many studies PCa consider in those patients whose cut-value was greater than twenty-five percent our research study are closely compared with them. In examine assessment of fPSA% has been high as compare to tPSA to reduce the difficulty of analysis of infected area i.e., PSA range from four to ten ng/ml & in our research study we examine perfection of fPSA% over tPSA among the analysis of the infected zone case. More over the role of PSAD for PCa is uneasy, we consider it higher bio marker over tPSA at a cut-off value less than point fifteen ng/ml/cm<sup>3</sup>. In the current research, ninety-seven.360 percent PCa was related with PSA density less point fifteen (Table II), which is dependable with many examinations clear that PSA density is frequently higher in PCa compared to nodular hyperplasia of prostate.

The aims of our current research study to compare the sensitivity, specificity and diagnostic efficiency with other related study (Table-III) showed the all bio markers and it perimeter in detail. In current study diagnostic accuracy significantly hopeful for each of these tests, the diagnostic efficiency of fPSA (at a cut of value of less than twenty five percent) & PSA density (at a cut of value of greater than point fifteen ng/ml/cm<sup>3</sup>) all the value of tumors marker of prostate cancer like PSA, total PSA, free PSA and PSAD and it sub perimeter sensitivity, specificity and diagnostic efficiency are discourse with detailed in the (Table-III) the deviation of each biomarker are shown in the above Figure-III.

### CONCLUSION:

These outcomes stress that diverse prostate-specific tumor markers have great diagnostic prediction with fPSA% & PSA Density have normally best diagnostic accuracy as compare to serum tPSA for PCa.

### REFERENCES:

1. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL. Increased specificity of PSA screening through measurement of percent free PSA. *J Urol* 1995;153(Suppl 1):312.
2. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson. G, Cuny C, et al. Measurement of the proportion of free-to-total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. *Urology* 1995;46:187-194.
3. Song JM, Kim C, Chung HC. 'Prostate specific antigen, digital rectal examination and transrectal ultrasonography: A meta-analysis for this

- diagnostic triad of prostate cancer in symptomatic Korean men'. *Yonesi Medical J* 2005;46:414-424.
4. Ishibe T, Usui T, Nihira H. Prognostic usefulness of serum acid phosphatase levels in carcinoma of the prostate. *J Urol* 1994; 112:237-240.
5. Talukder H, Jabeen S, Shaheen S, Islam MJ, Haque M. Hos-pital Cancer Registry, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh, Annual Report 2005.
3. Hernandez J, Thompson IM. Prostate-Specific Antigen: A Review of the Validation of the Most Commonly Used Can-cer Biomarker. *Cancer* 2004;101(5):894-904.
4. Freedland SJ, Partin AW. Prostate-specific antigen: Update 2006. *Urology* 2006; 67:458-460.
5. Fletcher CDM. 'Tumors of the male genital tract'. *Diagnos-tic Histopathology of tumors*. 3rd edition, Philadelphia, Elsevier, 2007: 755.
6. Brassell SA, Kao T, Sun L, Moul JW. PSA versus PSAD as predictor of tumor volume, margin status, pathologic stage and biochemical recurrence of prostate cancer. *Urology* 2005;66:1229-1233.
7. Curtis M, Arthur EC, Gerald PM, Georg B, Ants T, Robert B, et al. Association of Free PSA Percent, Total PSA, Age, and Gland Volume in the Detection of Prostate Cancer. *The Prostate* 1999;39:153-158.
8. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. *J Urol* 1992;147:815-816.
9. Catalona WJ, Antenor JAV, Roehl KA. Screening for prostate cancer in high risk populations. *J Urol* 2002;168:1980-1983.
10. Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, et al. Free to total prostate-specific antigen (PSA) ration is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. *Prostate (Suppl)* 1996;7:30-34.
11. Rommel FM, Augusta VE, Breslin JA, Huffnagle HW, Pohl CE, Sieber PR, et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. *J Urol* 1994;51(1):88-93.
12. Prestigiacomo AF, Stamey TA. Can free and total prostate specific antigen and prostate volume distinguish between men with negative and positive systematic ultrasound guided prostatic biopsies. *J Urol* 1997;157:189-194.